Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MedDay Pharmaceuticals
Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.
Novel Anti-Hypertensive Treatment & NSCLC Drug Among New EU Filings
The European Medicines Agency has added five new drugs to its latest monthly list of medicines that are under review for potential EU marketing approval.
Finance Watch: Biopharma Reckoning Brings Restructuring Plans, Consolidation
With cash preservation in mind, Rubius will dissolve, while EQRx, Impel, Cybin and Graphite cut jobs. Meanwhile, Jounce is restructuring and it plans to merge with Redx, yet the dually troubled firms MEI Pharma and Infinity will combine, while VBL will disappear in a reverse merger with Notable Labs.
Finance Watch: Founder-Friendly Curie.Bio Launches With $520m To Seed, Support New Companies
Private Company Edition: Alexis Borisy and his Curie.Bio co-founders will invest $5m-$7m to help companies get to lead optimization within 12-18 months. Also, Feng Zhang-founded Aera launched with $193m, Hexagon Bio raised a $77.3m series B round and Halda emerged with $76m.
- Other Names / Subsidiaries
- MedDay Pharmaceuticals SA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.